Assessment of Geriatric Evaluations Impact on New AML Guidance

Recruiting now

Conditions studied: AML, Adult

In brief

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Key facts

Study ID

NCT05909501

Run by

Abramson Cancer Center at Penn Medicine

People needed

100

Starts

2023-10-25

Expected to finish

2026-12-01

Last updated by the study team

2025-08-07

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
• New diagnosis being considered for new line of treatment
• Age ≥ 50 years.
• Performance status 0,1, and 2

You may not qualify if…

• Inability to understand or unable to sign a written informed consent
• Unable to fill out questionnaires on their own and/or do not have someone to help complete them

Where it is running

• Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.